UroGen Pharma Ltd.(URGN)

Sector:

Healthcare

Description:

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Current Price

$9.74

RSI

23.61

Market Capitalization:

246.4M

Beta:

1.223

Volume:

109,202

Analyst Target Price:

$ 39.8

Economiic Fair Price:


November 21, 2022
November 10, 2022
Q3
N/A
N/A
N/A
N/A
N/A
28.7M
73.7M
-5.07
-283.40 %
1.788
-1.485

-13.15 %
1.28 %
53.48 %
41.81 %
16.84 %
4.85 %

$ 48M
307.17 %
$ 11.8M
65450.00 %
$ 18K
-98.40 %
$ 1.1M
-86.17 %
$ 8.2M
-53.46 %
$ 17.5M

$ -85.6M
20.03 %
$ -107.1M
-50.12 %
$ -71.3M
-88.27 %
$ -37.9M
-285.02 %
$ -9.8M
-381.68 %
$ 3.5M

$ -109.4M
12.58 %
$ -125.1M
-18.99 %
$ -105.1M
-39.21 %
$ -75.5M
-278.02 %
$ -20M
-929.42 %
$ -1.9M

News

Press Releases

Notable Dates